BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

773 related articles for article (PubMed ID: 27385183)

  • 21. Cytochrome-P450-Mediated Drug
    Steyn SJ; Varma MVS
    Mol Pharm; 2020 Aug; 17(8):3024-3032. PubMed ID: 32589434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.
    Durmus S; Lozano-Mena G; van Esch A; Wagenaar E; van Tellingen O; Schinkel AH
    Mol Pharm; 2015 Dec; 12(12):4259-69. PubMed ID: 26474710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of Prediction Methods for Drug-Drug Interactions Based on the Construction of Physiologically Based Pharmacokinetic Models for Hepatic OATP Substrate Drugs and Endogenous Substrates].
    Yoshikado T
    Yakugaku Zasshi; 2023; 143(1):11-19. PubMed ID: 36596534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Hepatic Drug Transporters in Drug Development.
    Liu H; Sahi J
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S11-22. PubMed ID: 27385168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation.
    Bi YA; Kimoto E; Sevidal S; Jones HM; Barton HA; Kempshall S; Whalen KM; Zhang H; Ji C; Fenner KS; El-Kattan AF; Lai Y
    Drug Metab Dispos; 2012 Jun; 40(6):1085-92. PubMed ID: 22381335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?
    Rodrigues AD; Lai Y; Shen H; Varma MVS; Rowland A; Oswald S
    Drug Metab Dispos; 2020 Mar; 48(3):205-216. PubMed ID: 31879282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings.
    Yu J; Zhou Z; Tay-Sontheimer J; Levy RH; Ragueneau-Majlessi I
    J Pharm Sci; 2017 Sep; 106(9):2312-2325. PubMed ID: 28414144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.
    Kunze A; Huwyler J; Camenisch G; Poller B
    Drug Metab Dispos; 2014 Sep; 42(9):1514-21. PubMed ID: 24989890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Evaluation of Dehydroepiandrosterone Sulfate Potential to Predict Hepatic Organic Anion Transporting Polypeptide Transporter-Based Drug-Drug Interactions.
    Nishizawa K; Nakanishi T; Tamai I
    Drug Metab Dispos; 2017 Feb; 45(2):224-227. PubMed ID: 27934638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.
    Jones HM; Barton HA; Lai Y; Bi YA; Kimoto E; Kempshall S; Tate SC; El-Kattan A; Houston JB; Galetin A; Fenner KS
    Drug Metab Dispos; 2012 May; 40(5):1007-17. PubMed ID: 22344703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using the Dynamic Well-Stirred Model to Extrapolate Hepatic Clearance of Organic Anion-Transporting Polypeptide Transporter Substrates without Assuming Albumin-Mediated Hepatic Drug Uptake.
    Yan Z; Ma L; Hwang N; Huang J; Kenny JR; Hop CECA
    Drug Metab Dispos; 2024 May; 52(6):548-554. PubMed ID: 38604729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Mediated Drug Absorption, Clearance and Drug-drug Interactions.
    Taskar KS; Harada I; Alluri RV
    Curr Drug Metab; 2021; 22(7):523-531. PubMed ID: 33397250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in preclinical in vitro approaches towards quantitative prediction of hepatic clearance and drug-drug interactions involving organic anion transporting polypeptide (OATP) 1B transporters.
    Nozaki Y; Izumi S
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):56-70. PubMed ID: 31901416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.
    Feng B; Varma MV; Costales C; Zhang H; Tremaine L
    Expert Opin Drug Discov; 2014 Aug; 9(8):873-90. PubMed ID: 24857286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions.
    Lundquist P; Lööf J; Sohlenius-Sternbeck AK; Floby E; Johansson J; Bylund J; Hoogstraate J; Afzelius L; Andersson TB
    Drug Metab Dispos; 2014 Mar; 42(3):469-80. PubMed ID: 24396146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model.
    Varma MV; Bi YA; Kimoto E; Lin J
    J Pharmacol Exp Ther; 2014 Oct; 351(1):214-23. PubMed ID: 25107633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions.
    Kovacsics D; Patik I; Özvegy-Laczka C
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):409-424. PubMed ID: 27783531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dealing with the complex drug-drug interactions: towards mechanistic models.
    Varma MV; Pang KS; Isoherranen N; Zhao P
    Biopharm Drug Dispos; 2015 Mar; 36(2):71-92. PubMed ID: 25545151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry.
    Soars MG; Webborn PJ; Riley RJ
    Mol Pharm; 2009; 6(6):1662-77. PubMed ID: 19402709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.